TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating on November 1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tyler Van Buren has given his Hold rating due to a combination of factors related to Keros Therapeutics’ strategic focus and financial position. The company has decided to concentrate its efforts on KER-065, a promising candidate designed to enhance muscle and bone mass, with plans to initiate a Phase II trial for Duchenne Muscular Dystrophy (DMD) in early 2026, contingent on regulatory discussions. This strategic narrowing of focus suggests a cautious yet potentially rewarding approach, but it also implies a significant time horizon before any commercial success can be realized.
Furthermore, Keros maintains a robust cash position, with $695 million in cash and equivalents, expected to support operations into the first half of 2028. However, $375 million of this is earmarked for return to shareholders, which somewhat limits the available capital for immediate operational expansion. Additionally, while the partnership with Takeda for the development of elritercept presents a lucrative opportunity, the timeline for realizing substantial financial gains remains uncertain. These elements collectively contribute to the Hold rating, reflecting a balanced view of potential risks and rewards.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $16.50 price target.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KROS in relation to earlier this year.